| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GAL8 |
| Uniprot No | O00214 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-317aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMMLSLNNLQNIIYNPVIPFVGTIPDQLDPG TLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNT LINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRI GPEKIDTLGIYGKVNIHSIGFSFSSDLQSTQASSLELTEISRENVPKSGT PQLRLPFAARLNTPMGPGRTVVVKGEVNANAKSFNVDLLAGKSKDIALHL NPRLNIKAFVRNSFLQESWGEEERNITSFPFSPGMYFEMIIYCDVREFKV AVNGVHSLEYKHRFKELSSIDTLEINGDIHLLEVRSW |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GAL8(Galectin-8)重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Galectin-8 binds to LRRK2 and activates autophagy in Parkinson’s disease models*
**作者**：J. A. Smith et al.
**摘要**：本研究利用重组人GAL8蛋白，揭示其通过与帕金森病相关蛋白LRRK2相互作用激活自噬通路，为神经退行性疾病治疗提供潜在靶点。
---
2. **文献名称**：*Recombinant Galectin-8 production in E. coli: Structural insights and carbohydrate binding specificity*
**作者**：M. Tanaka et al.
**摘要**：报道重组GAL8在大肠杆菌中的高效表达及纯化方法，并通过晶体结构解析阐明其对β-半乳糖苷配体的特异性结合机制。
---
3. **文献名称**：*Galectin-8 as a pathogen receptor: Role in sensing bacterial glycans and triggering immune responses*
**作者**：C. Lee & R. García-Vallejo
**摘要**：证明重组GAL8通过识别沙门氏菌等病原体表面多糖，激活宿主细胞NF-κB信号通路，在先天免疫防御中发挥关键作用。
---
(注：以上文献信息为示例性内容，实际引用需以真实论文为准。)
**Background of GAL8 Recombinant Protein**
Galectin-8 (GAL8), a member of the galectin family of β-galactoside-binding proteins, plays multifaceted roles in cellular processes, including immune regulation, autophagy, and cell adhesion. Structurally, it contains two conserved carbohydrate recognition domains (CRDs) connected by a linker peptide, enabling it to bind glycan motifs on cell surfaces or extracellular matrices. Unlike other tandem-repeat galectins, GAL8 exhibits unique ligand specificity, preferentially recognizing poly-*N*-acetyllactosamine chains and sulfated glycans, which underpins its diverse biological functions.
GAL8 is implicated in innate immunity by acting as a danger sensor. It detects damaged endosomal or lysosomal membranes during pathogen invasion or cellular stress, triggering selective autophagy (xenophagy) or promoting inflammatory responses. Additionally, it modulates T-cell homeostasis and neutrophil activation, linking glycan-mediated signaling to immune regulation. In cancer, GAL8 exhibits context-dependent roles, either suppressing tumor growth by inducing apoptosis or promoting metastasis via interactions with integrins and extracellular matrix components.
Recombinant GAL8 is typically produced in *E. coli* or eukaryotic expression systems, enabling studies on its structure-function relationships and therapeutic potential. Its purified form is utilized in vitro and in vivo to investigate glycan-binding properties, autophagy pathways, and immune modulation. Recent studies also explore its application in targeted drug delivery due to its affinity for specific glycoconjugates.
Overall, GAL8 recombinant protein serves as a critical tool for deciphering galectin-mediated biological mechanisms and developing glycan-targeted therapies for infections, autoimmune diseases, and cancer.
×
